Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 414

1.
3.

Targeting heat shock proteins for immunotherapy in multiple myeloma: generation of myeloma-specific CTLs using dendritic cells pulsed with tumor-derived gp96.

Qian J, Wang S, Yang J, Xie J, Lin P, Freeman ME 3rd, Yi Q.

Clin Cancer Res. 2005 Dec 15;11(24 Pt 1):8808-15.

4.

Generation of potent antitumor CTL from patients with multiple myeloma directed against HM1.24.

Rew SB, Peggs K, Sanjuan I, Pizzey AR, Koishihara Y, Kawai S, Kosaka M, Ozaki S, Chain B, Yong KL.

Clin Cancer Res. 2005 May 1;11(9):3377-84.

5.
6.

Expression of CD56 by human papillomavirus E7-specific CD8+ cytotoxic T lymphocytes correlates with increased intracellular perforin expression and enhanced cytotoxicity against HLA-A2-matched cervical tumor cells.

Santin AD, Hermonat PL, Ravaggi A, Bellone S, Roman JJ, Jayaprabhu S, Pecorelli S, Parham GP, Cannon MJ.

Clin Cancer Res. 2001 Mar;7(3 Suppl):804s-810s.

PMID:
11300476
7.

Myeloma cells are highly sensitive to the granule exocytosis pathway mediated by WT1-specific cytotoxic T lymphocytes.

Azuma T, Otsuki T, Kuzushima K, Froelich CJ, Fujita S, Yasukawa M.

Clin Cancer Res. 2004 Nov 1;10(21):7402-12.

8.

[Induction of active antitumor immune response by myeloma idiotype protein-pulsed dendritic cells].

Yin XR, Zhang M, Luo YY, Lin X, He PC, Chen LM, Cai RB, Guo GL.

Ai Zheng. 2005 Jun;24(6):657-62. Chinese.

PMID:
15946473
9.

Sperm protein 17 (Sp17) is a suitable target for immunotherapy of multiple myeloma.

Chiriva-Internati M, Wang Z, Salati E, Bumm K, Barlogie B, Lim SH.

Blood. 2002 Aug 1;100(3):961-5.

12.

Ex vivo induction of multiple myeloma-specific cytotoxic T lymphocytes.

Hayashi T, Hideshima T, Akiyama M, Raje N, Richardson P, Chauhan D, Anderson KC.

Blood. 2003 Aug 15;102(4):1435-42.

13.

Whole-tumor-antigen-pulsed dendritic cells elicit cytotoxic T-cell response against pediatric nasopharyngeal carcinoma in vitro.

Yufeng D, Guocheng Z, Dongliang X, Rong F, Yuhong C, Ruying L, Jingshi Z, Xuhong Z.

Med Oncol. 2009;26(1):78-85. doi: 10.1007/s12032-008-9093-8.

PMID:
18810669
14.
15.

Alpha-type 1-polarized dendritic cells loaded with apoptotic allogeneic myeloma cell line induce strong CTL responses against autologous myeloma cells.

Yang DH, Kim MH, Hong CY, Lee YK, Jin CJ, Pham TN, Ahn JS, Bae WK, Kim YK, Chung IJ, Kim HJ, Kalinski P, Lee JJ.

Ann Hematol. 2010 Aug;89(8):795-801. doi: 10.1007/s00277-010-0931-3.

PMID:
20238114
16.

Induction of multiple myeloma-specific cytotoxic T lymphocyte stimulation by dendritic cell pulsing with purified and optimized myeloma cell lysates.

Lee JJ, Choi BH, Kang HK, Park MS, Park JS, Kim SK, Pham TN, Cho D, Nam JH, Kim YJ, Rhee JH, Yang DH, Kim YK, Kim HJ, Chung IJ.

Leuk Lymphoma. 2007 Oct;48(10):2022-31.

PMID:
17917970
17.

Induction of myeloma-specific cytotoxic T cells using dendritic cells transfected with tumor-derived RNA.

Milazzo C, Reichardt VL, Müller MR, Grünebach F, Brossart P.

Blood. 2003 Feb 1;101(3):977-82.

18.

Essential roles of perforin in antigen-specific cytotoxicity mediated by human CD4+ T lymphocytes: analysis using the combination of hereditary perforin-deficient effector cells and Fas-deficient target cells.

Yanai F, Ishii E, Kojima K, Hasegawa A, Azuma T, Hirose S, Suga N, Mitsudome A, Zaitsu M, Ishida Y, Shirakata Y, Sayama K, Hashimoto K, Yasukawa M.

J Immunol. 2003 Feb 15;170(4):2205-13.

19.

Induction of HM1.24 peptide-specific cytotoxic T lymphocytes by using peripheral-blood stem-cell harvests in patients with multiple myeloma.

Jalili A, Ozaki S, Hara T, Shibata H, Hashimoto T, Abe M, Nishioka Y, Matsumoto T.

Blood. 2005 Nov 15;106(10):3538-45.

20.

Tumor-specific recognition of human myeloma cells by idiotype-induced CD8(+) T cells.

Li Y, Bendandi M, Deng Y, Dunbar C, Munshi N, Jagannath S, Kwak LW, Lyerly HK.

Blood. 2000 Oct 15;96(8):2828-33.

Supplemental Content

Support Center